* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, RTW Biotech Opportunities's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities FCF Margin % vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's FCF Margin % distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RTW Biotech Opportunities (LSE:RTW) has a FCF Margin % of 31.06% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RTW Biotech Opportunities and its competitors. According to the industry distribution chart, RTW Biotech Opportunities ranks #504 out of 1465 companies in the Asset Management industry, placing it in the top 34.4%.
Is RTW Biotech Opportunities' FCF Margin % too high?
RTW Biotech Opportunities' current FCF Margin % is 31.06%. The Asset Management industry median FCF Margin % is 14.69. RTW Biotech Opportunities' value of 31.06% is 111.4% above this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #504 out of 1465 companies in the Asset Management industry, which is above the industry midpoint. Overall, RTW Biotech Opportunities has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' FCF Margin % compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #504 out of 1465 companies for FCF Margin %. This puts RTW Biotech Opportunities in the upper half of its industry. The industry median FCF Margin % is 14.69. RTW Biotech Opportunities' value of 31.06% is 111.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for an Asset Management company?
The median FCF Margin % among Asset Management companies is 14.69, based on 1,465 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current FCF Margin % of 31.06% is 111.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RTW Biotech Opportunities and its competitors. For the Asset Management industry, the median FCF Margin % is 14.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current FCF Margin % is 31.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current FCF Margin % of 31.06%. The current FCF Margin % is 31.06% and 111.4% above the Asset Management industry median of 14.69. RTW Biotech Opportunities' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current FCF Margin % is 31.06% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
36GF Score
Get the complete analysis for LSE:RTW
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
